Page last updated: 2024-12-08
2-n-hexyl-5-n-propylresorcinol
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
2-n-hexyl-5-n-propylresorcinol: produced by Pseudomonas B 9004; RN & N1 from 9th CI; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 197183 |
| CHEMBL ID | 496837 |
| CHEBI ID | 168034 |
| SCHEMBL ID | 5881393 |
| MeSH ID | M0058034 |
Synonyms (20)
| Synonym |
|---|
| 39341-78-1 |
| CHEBI:168034 |
| db-2073 |
| 2-hexyl-5-propylbenzene-1,3-diol |
| antibiotic db 2073 |
| resorcinol, 2-hexyl-5-propyl- |
| 1,3-benzenediol, 2-hexyl-5-propyl- |
| db 2073 |
| 2-hexyl-5-propyl-1,3-benzenediol |
| brn 1964593 |
| CHEMBL496837 |
| unii-e3bw82ch2t |
| e3bw82ch2t , |
| 2-n-hexyl-5-n-propylresorcinol |
| SCHEMBL5881393 |
| 2-hexyl-5-propyl resorcinol |
| LMPK15030002 |
| DTXSID10192566 |
| Q5204376 |
| 2-hexyl-5-propyl-resorcinol |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
| Class | Description |
|---|---|
| alkylbenzene | A monocyclic arene that is benzene substituted with one or more alkyl groups. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Bioassays (8)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID376305 | Antifungal activity against Candida albicans assessed as total inhibition of cell growth/spore germination after 24 hrs | 2006 | Journal of natural products, Apr, Volume: 69, Issue:4 | Antimicrobial dialkylresorcinols from Pseudomonas sp. Ki19. |
| AID376304 | Antifungal activity against Fusarium culmorum assessed as total inhibition of cell growth/spore germination after 72 hrs | 2006 | Journal of natural products, Apr, Volume: 69, Issue:4 | Antimicrobial dialkylresorcinols from Pseudomonas sp. Ki19. |
| AID376314 | Antibacterial activity against Staphylococcus aureus assessed as detectable inhibition of growth after 24 hrs | 2006 | Journal of natural products, Apr, Volume: 69, Issue:4 | Antimicrobial dialkylresorcinols from Pseudomonas sp. Ki19. |
| AID376307 | Antifungal activity against Drechslera sorokiniana assessed as detectable inhibition of growth after 48 hrs | 2006 | Journal of natural products, Apr, Volume: 69, Issue:4 | Antimicrobial dialkylresorcinols from Pseudomonas sp. Ki19. |
| AID376311 | Antibacterial activity against Staphylococcus aureus assessed as total inhibition of cell growth/spore germination after 24 hrs | 2006 | Journal of natural products, Apr, Volume: 69, Issue:4 | Antimicrobial dialkylresorcinols from Pseudomonas sp. Ki19. |
| AID376306 | Antifungal activity against Fusarium culmorum assessed as detectable inhibition of growth after 72 hrs | 2006 | Journal of natural products, Apr, Volume: 69, Issue:4 | Antimicrobial dialkylresorcinols from Pseudomonas sp. Ki19. |
| AID376309 | Antifungal activity against Aspergillus fumigatus assessed as total inhibition of cell growth/spore germination after 96 hrs | 2006 | Journal of natural products, Apr, Volume: 69, Issue:4 | Antimicrobial dialkylresorcinols from Pseudomonas sp. Ki19. |
| AID376310 | Antifungal activity against Aspergillus fumigatus assessed as detectable inhibition of growth after 96 hrs | 2006 | Journal of natural products, Apr, Volume: 69, Issue:4 | Antimicrobial dialkylresorcinols from Pseudomonas sp. Ki19. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (6)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (33.33) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.56
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||